Oragenics (OGEN)announced that, as previously disclosed in its 2025 Annual Report filed on March 16, the audited consolidated financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the company’s ability to continue as a going concern. The announcement is made pursuant to NYSE Company Guide which requires public announcement of the receipt of an audit opinion containing a going concern paragraph.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGEN:
- Oragenics files annual report on Form 10-K
- Oragenics initiates Phase IIa clinical trial site activation
- Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions
- Oragenics explores potential acquisition of additional assets in CNS space
- Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia